• Explore /
  • Poster
  • / A randomized phase II/III study to evaluate the safety and efficacy of disitamab vedotin (DV) plus toripalimab and chemotherapy/trastuzumab as first-line treatment for HER2-expressed, locally advanced, or metastatic gastric cancer.

A randomized phase II/III study to evaluate the safety and efficacy of disitamab vedotin (DV) plus toripalimab and chemotherapy/trastuzumab as first-line treatment for HER2-expressed, locally advanced, or metastatic gastric cancer.

Abstract Poster

Authors

null

Lin Shen

Department of GI Oncology, Peking University Cancer Hospital & Institute, Beijing, China

Lin Shen , Guoliang Ding , Dan Feng , Jianmin Fang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Small Bowel Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05980481

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr TPS427)

DOI

10.1200/JCO.2024.42.3_suppl.TPS427

Abstract #

TPS427

Poster Bd #

N12

Abstract Disclosures

Similar Posters

First Author: Yelena Y. Janjigian

First Author: Manish A. Shah

First Author: Haeseong Park

First Author: Josep Tabernero